Articles

Key View

• We forecast that real GDP will expand by 3.1% in Barbados in 2024, a solid performance given strong base effects.
• Private consumption will overwhelmingly be the main growth driver, underpinned by the strong performance of the tourism sector boosting employment and wages in the sector.
• The largest risk to growth is posed by any geopolitically

Key View

• UK drug shortages will likely persist due to ongoing post-Brexit access challenges, alongside wider regional supply chain issues. 
• The UK's pharmaceutical sector will continue to present a less attractive prospect for investment compared to EU markets.
• Amidst Brexit's complexities, the UK government will continue to introduce new measures to

Key View

• Nigeria is reportedly set to intensify the legal protection of broadband infrastructure, with the impending signing of an executive order that will criminalise the destruction of fibre-optic cables.
• The regulation may marginally improve operators' and investors' sentiment towards FTTx investment, although we note that the Sub-Sharan

Key View

• We maintain our forecast for the central bank to cut its policy rate from 4.5% to 4.0% by end-2024.
• We think the Bank will ease policy further to help ensure the economy meets the government’s GDP and credit growth targets, and relatively benign inflation will allow the Bank to cut.
• While recent dong weakness is a constraint, we do not think

Key View: Our outlook for German consumer spending over 2024 shows a slight yet modest rebound yet remains below pre-pandemic levels. Consumer confidence is stable but subdued, with retail sales weak amid ongoing economic challenges. Inflation pressures are expected to ease, while the labour market is relatively tight. Government interventions

Commodities displayed a stellar performance in April 2024 thus far, in general, with more sub-asset classes now seeing price appreciation in the year-to-date than not. 

In the main, renewed US dollar strength as markets continue to push back expectations for US Federal Reserve (Fed) rate cuts has failed to substantially pressure commodities priced

The Latest: On April 22, 2024, the European Commission (EC) granted approval to Samsung Bioepis’s Pyzchiva (ustekinumab), a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), thereby broadening the range of treatment options for patients with chronic inflammatory conditions. Pyzchiva is indicated for the treatment of plaque psoriasis

The Latest: In May 2024, AB Living which is a Spain-based property development group announced plans to open a new Almare resort in Isla Mujeres, Mexico in partnership with US-based hotels and resorts company Marriott International. The all-inclusive adult-only resort will be part of Marriott's Luxury Collection and will include 150-rooms, with